Inhibition of puerperal lactation: evaluation of bromocriptine and placebo.
Bromocriptine and placebo were randomly allocated to 50 patients who wished to suppress lactation. Patients on bromocriptine suffered no subjective symptoms such as breast pain and engorgement, and lactation was significantly reduced compared with patients on the placebo with or without breast binding. No side-effects were noted, and rebound lactation was seen in only 3 patients. In most patients contraceptives were commenced once the drug therapy ceased on the fourteenth day.
D000293:Adolescent; D000328:Adult; D000700:Analgesics / Q000008:administration & dosage; D001940:Breast; D001971:Bromocriptine / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008598:Menstruation; D008895:Milk, Human / Q000378:metabolism; D010146:Pain / Q000517:prevention & control; D010919:Placebos; D049590:Postpartum Period; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D013997:Time Factors
D000700:Analgesics; D010919:Placebos; D001971:Bromocriptine; D011388:Prolactin